Literature DB >> 12653682

Relationships between cholesterol homoeostasis and triacylglycerol-rich lipoprotein remnant metabolism in the metabolic syndrome.

Dick C Chan1, Gerald F Watts, P Hugh R Barrett, Frans H O'Neill, Trevor G Redgrave, Gilbert R Thompson.   

Abstract

The dysmetabolic syndrome of insulin resistance and visceral obesity is characterized by elevated plasma concentration of triacylglycerol-rich lipoprotein (TRL) remnants that may be related to increased cardiovascular risk. Perturbed hepato-intestinal cholesterol metabolism may play a contributory role in this abnormality. We therefore investigated the association between plasma markers of cholesterol absorption and synthesis with TRL remnant metabolism in 35 men with the metabolic syndrome (MS). Plasma campesterol:cholesterol and lathosterol:cholesterol ratios were measured as estimates of cholesterol absorption and synthesis respectively. Remnant metabolism was assessed by measuring remnant-like particle-cholesterol (RLP-C), apolipoprotein (apo)B-48 and the fractional catabolic rate (FCR) of a labelled remnant-like emulsion. Compared with controls, subjects with the MS had significantly lower plasma campesterol:cholesterol ratio, but higher lathosterol:cholesterol ratio ( P <0.05). Plasma RLP-C and apoB-48 concentrations were also higher ( P <0.01) and the remnant-like emulsion FCR was lower ( P <0.05). The plasma campesterol:cholesterol ratio was inversely correlated ( P <0.05) with plasma triacylglycerols ( r =-0.346), RLP-C ( r =-0.443), apoB-48 ( r =-0.427) and plasma lathosterol:cholesterol ratio ( r =-0.366); the campesterol:cholesterol ratio was also positively correlated with the remnant-like emulsion FCR ( r =0.398, P <0.05). In multiple regression analysis, the significant correlations between plasma campesterol:cholesterol ratio and plasma triacylglycerols, RLP-C, apoB-48 and FCR of the remnant-like emulsion were independent of age, dietary energy and plasma lathosterol. Our findings suggest that in subjects with the MS alterations in cholesterol absorption and synthesis may be closely linked with the kinetic defects in TRL metabolism.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12653682     DOI: 10.1042/cs1040383

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  8 in total

Review 1.  Pathophysiology of dyslipidaemia in the metabolic syndrome.

Authors:  G D Kolovou; K K Anagnostopoulou; D V Cokkinos
Journal:  Postgrad Med J       Date:  2005-06       Impact factor: 2.401

2.  Plasma lipids, lipoprotein metabolism and HDL lipid transfers are equally altered in metabolic syndrome and in type 2 diabetes.

Authors:  Vanessa M Silva; Carmen G C Vinagre; Luis A O Dallan; Ana P M Chacra; Raul C Maranhão
Journal:  Lipids       Date:  2014-04-10       Impact factor: 1.880

3.  Capsaicinoids lower plasma cholesterol and improve endothelial function in hamsters.

Authors:  Yin Tong Liang; Xiao-Yu Tian; Jing Nan Chen; Cheng Peng; Ka Ying Ma; Yuanyuan Zuo; Rui Jiao; Ye Lu; Yu Huang; Zhen-Yu Chen
Journal:  Eur J Nutr       Date:  2012-03-31       Impact factor: 5.614

4.  Inhibition of apoB secretion from HepG2 cells by insulin is amplified by naringenin, independent of the insulin receptor.

Authors:  Emma M Allister; Erin E Mulvihill; P Hugh R Barrett; Jane Y Edwards; Lindsey P Carter; Murray W Huff
Journal:  J Lipid Res       Date:  2008-06-27       Impact factor: 5.922

5.  Lipoprotein kinetics in the metabolic syndrome: pathophysiological and therapeutic lessons from stable isotope studies.

Authors:  Dick C Chan; P Hugh R Barrett; Gerald F Watts
Journal:  Clin Biochem Rev       Date:  2004-02

6.  Postprandial lipemia in men with metabolic syndrome, hypertensives and healthy subjects.

Authors:  Genovefa D Kolovou; Katherine K Anagnostopoulou; Antonis N Pavlidis; Klelia D Salpea; Stella A Iraklianou; Konstantinos Tsarpalis; Dimitris S Damaskos; Athanasios Manolis; Dennis V Cokkinos
Journal:  Lipids Health Dis       Date:  2005-09-30       Impact factor: 3.876

7.  High Remnant Cholesterol Level Potentiates the Development of Hypertension.

Authors:  Ming-Ming Chen; Xuewei Huang; Chengsheng Xu; Xiao-Hui Song; Ye-Mao Liu; Dongai Yao; Huiming Lu; Gang Wang; Gui-Lan Zhang; Ze Chen; Tao Sun; Chengzhang Yang; Fang Lei; Juan-Juan Qin; Yan-Xiao Ji; Peng Zhang; Xiao-Jing Zhang; Lihua Zhu; Jingjing Cai; Feng Wan; Zhi-Gang She; Hongliang Li
Journal:  Front Endocrinol (Lausanne)       Date:  2022-02-09       Impact factor: 5.555

8.  Empagliflozin decreases remnant-like particle cholesterol in type 2 diabetes patients with insulin resistance.

Authors:  Sachiko Hattori
Journal:  J Diabetes Investig       Date:  2017-12-27       Impact factor: 4.232

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.